Market Indices
Sector Heatmap
PBM — Psyence Biomedical Ltd. Common Shares
NasdaqPsyence Biomedical Ltd. Common Shares
- O
- 4.93
- H
- 5.10
- L
- 4.84
- V
- 16.2K
PBM — Latest News & Headlines
20 StoriesA Texas drugmaker says it holds about half the U.S. quota for a drug studied for addiction. Psyence partnered with it. - Stock Titan
A Texas drugmaker says it holds about half the U.S. quota for a drug studied for addiction. Psyence partnered with it. Stock Titan
How PBM Reform Is Reshaping the Operational Environment for Pharma Manufacturers - Pharmaceutical Commerce
How PBM Reform Is Reshaping the Operational Environment for Pharma Manufacturers Pharmaceutical Commerce
Should CVS Health (CVS) Investors Worry About Its Care Push And PBM Scrutiny? - Simply Wall Street
Should CVS Health (CVS) Investors Worry About Its Care Push And PBM Scrutiny? Simply Wall Street
Smart Ring Maker Oura Delays IPO Due to Market ‘Uncertainty’ - Modern Healthcare
Smart Ring Maker Oura Delays IPO Due to Market ‘Uncertainty’ Modern Healthcare
Regeneron and Sanofi Expand Antibody Alliance with Four New Drugs - Pharmaceutical Executive
Regeneron and Sanofi Expand Antibody Alliance with Four New Drugs Pharmaceutical Executive
Insurer-owned PBMs lose ground in commercial plan market - BenefitsPRO
Insurer-owned PBMs lose ground in commercial plan market BenefitsPRO
A passive holder reports more than 5% of Psyence Biomedical (PBM) common shares. - Stock Titan
A passive holder reports more than 5% of Psyence Biomedical (PBM) common shares. Stock Titan
Why Waltz Health, Fresenius Kabi Are Taking Biosimilars Direct - Pharmaceutical Commerce
Why Waltz Health, Fresenius Kabi Are Taking Biosimilars Direct Pharmaceutical Commerce
Cigna Group (CI) Could Be 58% Undervalued On PBM And Claims Review Concerns - Simply Wall Street
Cigna Group (CI) Could Be 58% Undervalued On PBM And Claims Review Concerns Simply Wall Street
What Oura’s IPO could mean for digital health - Modern Healthcare
What Oura’s IPO could mean for digital health Modern Healthcare
Ibogaine has no therapeutic approval. Psyence Biomedical (PBM) unit signs a U.S. manufacturing deal. - Stock Titan
Ibogaine has no therapeutic approval. Psyence Biomedical (PBM) unit signs a U.S. manufacturing deal. Stock Titan
GLP-1 Payment Risks: What Pharmacies Should Review with Their Processor - Pharmaceutical Commerce
GLP-1 Payment Risks: What Pharmacies Should Review with Their Processor Pharmaceutical Commerce
A deal with a shareholder would give Psyence Biomedical’s (PBM) subsidiary exclusive U.S. ibogaine rights. - Stock Titan
A deal with a shareholder would give Psyence Biomedical’s (PBM) subsidiary exclusive U.S. ibogaine rights. Stock Titan
SEC Filings for Oct 5, 2026 - 10-K, 10-Q, 8-K Forms - Stock Titan
SEC Filings for Oct 5, 2026 - 10-K, 10-Q, 8-K Forms Stock Titan
CVS Health (CVS) On New Distribution Deals And Why The Stock Still Looks Undervalued - Simply Wall Street
CVS Health (CVS) On New Distribution Deals And Why The Stock Still Looks Undervalued Simply Wall Street
How Data Lawsuit Settlement Will Impact CVS Health Stock Investors - Simply Wall Street
How Data Lawsuit Settlement Will Impact CVS Health Stock Investors Simply Wall Street
Distribution Deal Extension Could Be A Big Deal For CVS Stock (CVS) - Simply Wall Street
Distribution Deal Extension Could Be A Big Deal For CVS Stock (CVS) Simply Wall Street
Cigna Corp (CI) Stock Price Today: $273.75 - Pluang
Cigna Corp (CI) Stock Price Today: $273.75 Pluang
Rightway Eyes IPO After $1.75B Valuation - Briefs Finance
Rightway Eyes IPO After $1.75B Valuation Briefs Finance
Medicare Advantage insurers pull back even further - Modern Healthcare
Medicare Advantage insurers pull back even further Modern Healthcare